RESEARCH ARTICLE

Cyclical DNA Methylation and Histone Changes Are Induced by LPS to Activate COX-2 in Human Intestinal Epithelial Cells

Tiziana Angrisano1*, Raffaela Pero2,3*, Mariarita Brancaccio2, Lorena Coretti2,3, Ermanno Florio2,3, Antonio Pezone2,3, Viola Calabrò1, Geppino Falco1, Simona Keller2,3, Francesca Lembo4, Vittorio Enrico Avvedimento2, Lorenzo Chiariotti2,3*

1 Dipartimento di Biologia, Università degli Studi di Napoli “Federico II”, Monte Sant’Angelo via Cintia 21, 80126 Naples, Italy, 2 Dipartimento di Medicina Molecolare e Biotecnologie Mediche, via S. Pansini, 5, 80131 Naples, Italy, 3 Istituto di Endocrinologia ed Oncologia Sperimentale C.N.R., via S. Pansini, 5, 80131 Naples, Italy, 4 Dipartimento di Farmacia, Università degli Studi di Napoli “Federico II”, via D. Montesano 47, 80131 Naples, Italy

* These authors contributed equally to this work.

* tangrisa@unina.it (TA); chiariot@unina.it (LC)

Abstract

Bacterial lipopolysaccharide (LPS) induces release of inflammatory mediators both in immune and epithelial cells. We investigated whether changes of epigenetic marks, including selected histone modification and DNA methylation, may drive or accompany the activation of COX-2 gene in HT-29 human intestinal epithelial cells upon exposure to LPS. Here we describe cyclical histone acetylation (H3), methylation (H3K4, H3K9, H3K27) and DNA methylation changes occurring at COX-2 gene promoter overtime after LPS stimulation. Histone K27 methylation changes are carried out by the H3 demethylase JMJD3 and are essential for COX-2 induction by LPS. The changes of the histone code are associated with cyclical methylation signatures at the promoter and gene body of COX-2 gene.

Introduction

Inflammation, specifically proinflammatory prostanoids, greatly contribute to shape tumor microenvironment and to neoplastic progression [1]. Bacterial lipopolysaccharide (LPS) induces epithelial and immune cells to release mediators such as prostaglandins, which are synthesized by cyclooxygenase-2 (COX-2). COX-2 is directly involved in the development of chronic inflammation, including inflammatory bowel disease [2, 3]. COX-2 is an immediate-early response gene induced locally by LPS and pro-inflammatory cytokines [4, 5]. COX-2 expression levels are upregulated in a significant fraction of colorectal adenomas and adenocarcinomas [6–8]. COX-2 products induce changes in cell adhesion properties enhancing the metastatic potential. High levels of COX-2 are associated with poor prognosis [9, 10]. Regular use of COX inhibitors greatly reduces the relative risk of developing colon cancer and contrasts cancer stemness [11, 12]. COX-2 expression is regulated by epigenetic mechanisms. For
example, COX-2 gene is frequently methylated and silenced in a subset of colorectal tumors (CIMP+ tumors) [13]. Also, in chronic inflammation induced by Helicobacter pylori (Hp) infection, COX-2 is modulated by DNA methylation [14]. At this stage, mechanisms underlying LPS-induced COX-2 gene modulation and programming have been only partly addressed. However, epigenetic changes in host cells induced by LPS have been recently investigated [15–20]. We have previously shown that Hp induces specific epigenetic events at COX-2 and iNOS promoter regions in the first phases of exposure of gastric cells to Hp [18, 19]. Furthermore, in intestinal epithelial cells LPS activates IL-8 gene expression by inducing rapid histone modifications in the IL-8 promoter chromatin [17].

In this work, we investigated whether LPS exposure affects epigenetic signatures at COX-2 gene in intestinal epithelial cells. We show that LPS induces cycles of methylation in the DNA and in histone H3 around the COX-2 promoter. Specifically, methylation cycles of H3 lysine 27, a repressive mark associated with transcription inhibition, are induced by LPS and carried out by the H3K27 demethylase JMJD3 to activate COX-2 gene in intestinal epithelial cells.

Materials and Methods

Cell culture and treatments

The human intestinal epithelial cell lines HT-29 (Organism Homo sapiens, human/tissue colon/disease: colorectal adenocarcinoma) was purchased by ATCC™ HTB-38™ [17] were grown in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum (Life Technologies), 2 mM glutamine, penicillin (25 U/mL) and streptomycin (25 mg/mL) in a 5% CO2 atmosphere at 37°C. Cells were pretreated with Human interferon-γ (IFN-γ) (Roche Applied Science, Germany) 10 ng/ml for 12 hours or control medium as previously described in [21], washed, and then stimulated with LPS 50 ng/ml at different times. LPS (Escherichia coli, O55:B5) were purchased from Sigma-Aldrich (St. Louis, MO) and reconstituted in endotoxin-free water.

Databases

Gene sequences were retrieved by the Ensembl database: COX-2, accession number ENST00000367468.

Quantitative RT-PCR analysis

Total RNA was isolated with RNaseasy extraction kit QIAGEN (Qiagen,GmBh) according to the manufacturer instructions. 1 μg of total RNA of each sample was reverse-transcribed with QuantiTect Reverse Transcription (Qiagen) using an optimized blend of oligo-dt and random primers according to the manufacturer’s instructions as described in [22]. Quantitative PCR amplifications were performed using QuantiTect SYBR Green (Qiagen) in a Chromo4 Real Time thermocycler (BIORAD). Following primers were used for COX-2 cDNA amplification: (COX2F) 5' −TCACGCATCAGTTTTTCAAGA−3' and (COX2R) 5' −TCACCGTAAAATATGATTATAATGCAC−3'; EZH2fw 5' −TGTGGATACTCCTCCAAGGAA−3' and EZH2rv 5' −GAGGAGCCTGCCCTTTTTCA−3'; Primers for evaluation of JMJD3 expression were purchased from Qiagen (Hs_JMJD3_1_SG; Quantitect Primer Assay, QIAGEN); G6PD and 18S rRNA genes were used as housekeeping genes for PCR reaction: G6F (forward) 5' −ACACAGGTGAGCCCTTCTTCAA−3' and G6R (reverse) 5' −GGAGGCTGATCATGCTACT−3' and 18SF; (forward) 5' −GGGCTACACTGACTGGCTC−3' and 18SR (reverse) 5' −CATCCAAA TCGTTAGTACGC−3'. The quantitative PCR conditions were: 95°C for 15 min followed by 40 cycles of 95°C for 15 s, 59°C for 30 s, and 72°C for 30 s. Calculations of relative expression
levels were performed using the $2^{-\Delta\Delta Ct}$ method [23] and take into account the values of at least three independent experiments.

**Quantitative ChIP analysis**

ChIP analysis was performed as previously described [24] using the EpiQuikTM chromatin immunoprecipitation kit from Epigentek Group Inc. (Brooklyn, NY). Specifically, $0.5 \times 10^6$ cells treated or untreated were grown to 80%-90% confluency on a 100 mm plate, then trypsinized, collected and washed with PBS. The cells were cross-linked in fresh culture medium with 1% formaldehyde and blocked with 1.25 M Glycine solution. After washing with PBS (2x) the samples were immunoprecipitated with the antibodies according the manufacturers’ instructions. Antibodies used for Protein-DNA immunoprecipitation were: anti-H3-Acetyl (Upstate cat#06–599), anti di-methyl-H3K9 (Upstate cat#07–214), anti tri-methyl-H3K27 (Upstate cat#07–449, Biotechnoloy, Dundee, UK) anti-di-methyl-H3K4 (Abcam Inc. cat#ab7766), anti-JMJD3 (ABGENT, cat#AP1022a, San Diego; CA), anti-EZH2 (Cell Signaling TECHNOLOGY, cat#AP1022a, Danvers, MA) and normal mouse IgG as a negative control antibody. DNA samples were subjected to quantitative PCR analyses, using SYBR<sup>®</sup> Green Taq (Qiagen) in a Chromo4 Real Time thermocycler (BIORAD). Amplification of the COX-2 promoter was performed using the primers: PCXF 5’-AAGGGGAGAGGAGGGAAAAATTTGTG-3’ (position from nucleotides -89 to -114) and PCXR, 5’-GAGGCGCTGCTGAGGAGTTCCTG-3’ (position from nucleotides +44 to +66). The quantitative PCR conditions were: 95°C for 15 min followed by 40 cycles of 95°C for 15 sec, 62°C for 30 sec, and 72°C for 30 sec. The signal obtained by precipitation with the control IgG was subtracted from the signals obtained with the specific antibodies. Results are expressed as percentage of the input, and calculations take into account the values of at least three independent experiments.

**Gene silencing by RNA interference**

HT-29 cell lines were plated at a density of 50% per 6-well plates 24 hrs before transfections. Cells were transfected with JMJD3 siRNA (Qiagen, Hs_jmjd3_2, SI00449827, target sequence: cagcaggaatgccaaggtgaa) or AllStars negative Control siRNA (Qiagen, 1027281) at a final concentration of 5nM using Lipofectamine<sup>®</sup> Transfection Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Twenty-four hours after transfection, cells were treated with LPS (50 ng/ml), then harvested at the indicated time points and subjected to mRNA and ChIP analyses as described above.

**DNA methylation analysis by MALDI-TOF**

**Sodium bisulfite treatment.** Genomic DNA was isolated with DNeasy extraction kit (Qiagen) according to the manufacturer instructions. Sodium bisulfite conversion was performed using EZ DNA Methylation Kit (Zymo Research, CA USA). One μg for each sample of genomic DNA, eluted in 30 μL of H<sub>2</sub>O, was used for bisulfite treatment. Amplicons used for methylation analysis were obtained from 50 ng of bisulfite treated genomic DNA.

MALDI-TOF analysis. We used SEQUENOM MassARRAY platform for DNA methylation analysis. PCR primers to analyze human COX-2 (Upper and Lower strand), designed by using MetHprimer (www.urogene.org/metHprimer), were: LCXF, 5’-aggaagagagGGAGTATGGGATAGATTAGGAG-3’ and LCXR, 5’-cagtaatacagctcataactagggaggaaggctTACCCCCCTCAACCACCAAATT-3’, to analyze the region from -218 to +277; UCFX, 5’-aggaagagagTTTTGTTTCCTCCAAATTGGGTAGTTTTGTG-3’ and UCXR, 5’-cagtaatacagctcataactagggaggaaggctACTAAAAATACCCAAAAATCAAAAAC-3 to analyze the region from -213 to +272; for reverse primer, an additional T7 promoter tag for in
vitro transcription was added, as well as a 10-mer tag on the forward primer to adjust for melting-temperature differences. Sequences of these tags are indicated in lower case. The reaction protocol was previously described [25]. Mass spectra were acquired by using a MassARRAY Compact MALDI-TOF (Sequenom) and spectra's methylation ratios were generated by the Epityper software v1.0 (Sequenom).

Statistical Analysis

Statistical significance between groups was assessed by Student's t test. Data are expressed as means ± standard deviation (SD). All experiments were repeated at least three times. A p value < 0.01 and 0.05 was considered to be statistically significant.

Results

LPS induces COX-2 gene in HT-29 intestinal cells

To investigate COX-2 promoter (Fig 1A) regulation, we first determined the changes in COX-2 mRNA levels induced by LPS in HT-29 human intestinal epithelial cells. HT-29 cells, primed with IFN-γ were treated with LPS, then COX-2 mRNA levels were measured by real-time PCR at different time points (Fig 1B). COX-2 mRNA levels markedly increased in response to LPS, peaking at 1 hour after stimulation with 50 ng/ml LPS (Fig 1B) and then gradually decreased over time. We noticed two peaks of COX-2 mRNA levels at 1h and 6h of LPS treatment, suggesting that LPS induces cyclic transcriptional events to activate COX-2 expression in HT-29 cells.

LPS-dependent histone modifications at COX-2 promoter

Histone methylation and acetylation at the COX-2 promoter chromatin following LPS stimulation were analyzed by ChIP assays using anti-acetylated H3, dimethylated H3K4 (H3K4me2), dimethylated H3K9 (H3K9me2) and trimethylated H3K27 (H3K27me3) antibodies (Fig 2A). We found that the chromatin activation marks, H3K4me2 and H3 acetyl, increased significantly at COX-2 promoter chromatin 1 hour after LPS stimulation returning to basal levels at 12–24 hours time points (Fig 2A). Similarly to mRNA accumulation, there are two peaks, at 1 and 6 h after LPS exposure, of H3K4me2 levels (compare Figs 1B and 2A). Conversely, the repressive chromatin marks, H3K9me2 and H3K27me3 displayed an opposite pattern of cyclical changes upon LPS. Specifically, H3K27me3 levels were high in untreated HT-29 cells, decreased at 1 h, partially restored at 2 h and again decreased at 6 h time points after LPS treatment. At 12–24 hours H3K27me3 levels were similar in stimulated and unstimulated cells (Fig 2A). H3K9me2 levels displayed a single cycle, because they decreased early (1h LPS) and returned to the levels of unstimulated cells thereafter. These data suggest that H3K27 methylation changes may be relevant for LPS induction of COX-2 gene and that they may be dependent on changes in the levels or the recruitment of H3K27 methylase and demethylase enzymes (namely, EZH2 and JMJD3) upon LPS stimulation. To define more precisely this point, we analysed first the concentration of these two enzymes following LPS stimulation. Fig 2B shows that EZH2 expression was significantly and rapidly (1 hour) reduced by LPS, while JMJD3 levels were significantly induced by LPS and remained high up to 6 h of LPS stimulation. Second, we analyzed the recruitment of EZH2 and JMJD3 at the COX-2 promoter upon LPS stimulation. Fig 2C shows that JMJD3 recruitment at COX-2 promoter displayed the same cyclical changes of the activation marks (Fig 2A, left panels). As expected, the pattern observed in the recruitment of JMJD3 was reciprocal to that of its natural substrate, H3K27me3 (Fig 2C left panel and Fig 2A right panels). Collectively, LPS induced at COX-2 promoter a cyclical loss
and gain of repressive and activation markers, respectively. These oscillatory cycles of epigenetic markers faithfully reflect COX-2 mRNA accumulation in response to LPS.

**JMJD3 depletion inhibits COX-2 induction by LPS**

To investigate the role of JMJD3 demethylase in LPS-induced COX-2 activation, we performed a JMJD3 knock-down experiment. HT-29 cells were transfected with JMJD3 siRNA and JMJD3 and COX-2 mRNA levels were measured by qRT-PCR. In LPS-untreated siRNA-transfected cells, JMJD3 expression decreased more than 70% and did not increase upon LPS treatment (Fig 3). COX-2 induction by LPS was completely inhibited in JMJD3-depleted cells.
Fig 2. Epigenetic dynamics of LPS-induced COX-2 activation at the COX-2 gene promoter region. (A) LPS induces histone modification changes at the COX-2 gene promoter region. Chromatin changes at COX-2 promoter were analyzed by ChIP assays. Controls include untreated (CTRL) and IFN-γ pretreated (0) HT-29 cells. Chromatin from controls and from HT-29 cells treated with LPS for 1, 2, 6, 12, 24 hours, was immunoprecipitated with the indicated antibodies. Each experiment was repeated at least three times, and the data are presented as percentages of input DNA (mean ± SD). *, p < 0.01; **, p<0.05; (B) Total RNA was extracted at the indicated time points after treatment with LPS and subjected to qRT-PCR.
analyses of histone demethylases JMJD3 and methyltransferases EZH2. The mRNA levels were normalized to G6PD levels and expressed relative to control cells (CTRL). ChIP experiments were performed with anti-JMJD3 and anti-EZH2 antibodies. COX-2 promoter DNA sequences recovered after the indicated treatments were quantified by real-time PCR. Each experiment was repeated at least three times, and the data are presented as percentages of input DNA (mean ± SD). *, p < 0.01; **, p < 0.05.

doi:10.1371/journal.pone.0156671.g002

Dynamic changes of CpGs methylation at the COX-2 promoter

Histone H3 methylation changes can be associated with DNA methylation patterns [26]. Specifically, we have previously described that rapid transient DNA methylation changes at the COX-2 promoter are associated with transcriptional activation and precede histone modifications in gastric cells exposed to Helicobacter pylori [18]. Along the same line, here, we investigated the DNA methylation dynamics at COX-2 promoter in LPS-treated HT-29 cells. Twenty-two CpG sites located in the COX-2 promoter region were analyzed by MALDI-TOF MS technique (Sequenom), on both lower and upper strands (Fig 4). DNA methylation was evaluated during the first 2 h of LPS exposure at intervals of 10 minutes in order to be able to detect possible transient changes. Fig 4 shows cycles of methylation/demethylation with a 40 min period upon LPS exposure. CpGs upstream or around the transcription start site (TSS) were methylated and demethylated in a strand specific fashion (-176 and +25 from TSS). Conversely, the CpGs in the body of the gene were methylated-demethylated symmetrically on both strands. It is worth noting that some CpGs were methylated-demethylated only during the first cycle (40 min), while others (+108/115, +124/127, +132, +139/145, +171, +198/208, +217, +225/231) displayed one or more methylation cycles with a 40 min interval between the peaks (Fig 4).

Collectively, these results show very similar oscillatory patterns of DNA and histone methylation changes induced by LPS. The timing of these cycles suggest that DNA methylation changes precede or are synchronous with histone H3K27 demethylation events induced by LPS and carried out by JMJD3. It remains to be seen whether the two events are causally linked.

Discussion

In the present study, we describe the chromatin and DNA methylation changes occurring at the promoter of COX-2 gene in intestinal epithelial cells as direct consequence of LPS exposure. LPS-dependent COX-2 gene activation was marked by transient cyclic epigenetic events including increase of H3 acetylation and H3K4me2 activation marks, decrease of H3K9me2 and H3K27me3 repressive marks and early cyclic DNA methylation/demethylation events at specific CpG sites of COX-2 gene-regulatory region. Most importantly, we found that JMJD3 demethylase was enriched at COX-2 promoter in concomitance with depletion of H3K27me3 levels and displacement of EZH2, a H3K27 methylase. Finally, the essential role of JMJD3 was assessed by siRNA experiments.

Cycles of histone H3K27 methylation induced by LPS at the COX-2 promoter

Ours and others’ recent studies demonstrate that bacteria, or their components such as LPS, are able to induce changes in histone modifications in exposed cells, thereby altering the host’s
Fig 3. Histone H3K27 demethylase (JMJD3) silencing by siRNA modifies COX-2 expression and histone modifications dynamics during LPS treatment. (A) COX-2 and JMJD3 expression in the presence (grey bars) or absence (black bars) of JMJD3 siRNA during LPS treatment. Time points after LPS administration are indicated. COX-2 and JMJD3 expression was analyzed by qRT-PCR using primers reported in Material and Methods section. JMJD3 levels were normalized to G6PD or 18S rRNA levels and expressed relative to control cells (CTRL1 and CTRL2, respectively). COX-2 levels were normalized to G6PD levels and expressed relative to control cells (CTRL). Data points represent the average of triplicate determinations ± SD. *p<0.01; **p<0.05. (B) H3K27me3 modulation by LPS treatment at COX-2 promoter was evaluated in the presence of JMJD3 siRNA (grey bars) or negative control siRNA (black bars). Recovered COX-2 promoter DNA sequences after ChIP experiments were quantified by qRT-PCR. Each experiment was repeated at least three times, and the data are presented as percentages of input DNA (means±SD). *p<0.05. Note that the control experiments were repeated along with siRNA experiments giving results similar to those showed in previous figures.

doi:10.1371/journal.pone.0156671.g003
Fig 4. Cycles of DNA methylation in COX-2 gene induced by LPS. Left: percentage of methylation at the indicated CpG sites on upper and lower strands. ‘Time 0’ indicates the methylation status in untreated HT-29 cells. The time scale includes intervals of 10 min for a total of two-hour time course, as indicated. Right: Structure of the human COX-2 gene. Regulatory upstream region (open box), proximal NF-κB binding site, CRE and TATA domains (white boxes), AP-2 and AP-1 (black boxes), exon I (gray box) are indicated. CpG sites (horizontal bars) on the left side were selected because showed significant changes in DNA methylation and the results are shown in the correspondent graphs. TSS (arrow) and the positions of the primers are indicated (UCXF, UCXR for upper strand and LCXF, LCXR for lower strand amplification).

doi:10.1371/journal.pone.0156671.g004
transcriptional program and possibly affecting the host innate immune response [15–20]. However, the majority of the previous studies were carried out in immune cells (neutrophils, monocytes, macrophages and dendritic cells) [27] while it is not well known the response to LPS of epithelial cells, which represent the first barrier against microbes. Moreover, most of studies addressing LPS-induced epigenetic modifications at COX-2 gene were focused on histone phosphorylation and acetylation dynamics and few on histone and DNA methylation [15, 16, 28, 29]. In an early study [30] it was reported that LPS induced IL-12 production by a rapid and specific nucleosome re-organization at IL-12 promoter region in murine macrophages. Transient changes in H3 acetylation and H3K4, H3K9 and H3K27 methylation in IL-8 gene promoter were induced by LPS and pretreatment of HT-29 colon cancer cells with deacetylase inhibitors amplified LPS-induction of IL-8 [17]. A more precise analysis overtime of histone H3K27 methylation at the COX-2 promoter reveals at least 2 cycles of methylation involving H3K27. JMJD3 demethylase seems an important mediator of LPS induced H3-K27 methylation cycles, because depletion of this enzyme severely impairs LPS induction of COX-2 and abolishes H3K27 methylation cycles (Fig 3). However, recruitment of the demethylase (JMJD3) and the loss of the methyltransferase (EZH2) at the COX-2 promoter is steady and progressive (Fig 2B), suggesting that not the concentration but the activation of JMJD3 is cyclical. We propose that methylation cycles of H3K4 and H3K27 follow reciprocal patterns (Fig 2A). Methylation of H3K4 transiently halts demethylation of H3K27 and this allows the ordered recruitment of transcription initiation factors. These events impact also on RNA accumulation, because we observed a cycle also at COX-2 RNA levels following LPS challenge. We wish to stress that we could detect these cycles (RNA included) because the cells have been synchronized in two steps and are responsive to LPS stimulus. With the time 6–12 hours after the initial LPS challenge, transcription stochastically desynchronizes and the histone methylation-demethylation cycles are not detectable (Fig 2). Finally, the simultaneous presence of H3K9 and H3K27 methylation marks at COX-2 gene promoter region has been previously suggested to contribute to the maintenance of constitutive heterochromatin and more stable gene silencing [31]. However, our data show that LPS stimulation is able to induce rapid and simultaneous loss of both repressive marks at COX-2 promoter.

Cycles of CpG methylation induced by LPS at the COX-2 gene

The most striking finding presented here is the temporal association between histone H3K27 and H3K4 methylation cycles with methylation cycles of selected CpGs in COX-2 gene. There are similar examples of cyclical DNA methylation in genes induced by estrogens [32, 33] or cyclical histone H3 K9 and K4 methylation in genes induced by retinoic acid [34]. This is the first example of temporal correlation between histone and DNA methylation. Although we have not clarified the mechanistic link between the two methylation events, we note some specific signatures of the CpGs undergoing to methylation cycles around the TSS of COX-2 gene upon LPS challenge. The CpGs in the promoter region (-176 and +25) were transiently methylated in the minus strand only, while the CpGs in the body of the gene (+108 to +225) underwent periodic methylation on both strands (Fig 4), similarly to CpGs in estrogen responsive genes [32, 33]. Moreover, some CpGs displayed a single methylation cycle at 40 min of LPS exposure, while others were periodically methylated in two methylation-transcription cycles, or in three cycles (+135 and +217), with a time interval period of 40 minutes between each cycle (Fig 4). We hypothesize that these epigenetic changes define a specific transcription territory in or around the gene and its regulatory regions. For example, these transient and differential methylation marks may differentially label the regulatory regions and the gene body.
Overall, we believe that the analysis of the epigenetic changes induced by LPS to activate COX-2 provides a specific temporal window on the early phases of transcription. Moreover, because aberrant methylation of COX-2 is frequent in colon cancer [13], it will be very important to investigate whether transient cyclical methylation occurring during transcription cycles may become inaccurate and distorted thus potentially contributing to aberrant methylation changes at COX-2 gene promoter during neoplastic progression.

Acknowledgments
This work was supported by grant from Epigenomics Flagship Project—EPIGEN, C.N.R. to LC, by POR Campania FSE 2007–2013, Project CRÈME, to TA, by Regione Campania, L.5, to LC, and by Associazione Italiana per la Ricerca sul Cancro—AIRC (IG 16983) to VEA. Lorena Coretti, fellowship by EPIGEN Flagship Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Author Contributions
Conceived and designed the experiments: TA RP LCh VEA. Performed the experiments: TA RP MB AP. Analyzed the data: TA RP VC GF VEA LCh. Contributed reagents/materials/analysis tools: FL SK EF LCo. Wrote the paper: TA RP FL VEA LCh.

References
1. Wang D, DuBois RN (2008) Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Letter 267(2):197–203.
2. Singh VP, Patil CS, Jain NK, Singh A, Kulkarni SK (2003) Effect of nimesulide on acidic acid- and leukotriene-induced inflammatory bowel disease in rats. Prostaglandins Other Lipid Mediat 71(3–4):163–175. PMID: 14518559
3. Deb Nath T, Kim da H, Lim BO (2013) Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease. Molecules 18(6):7253–7270. doi: 10.3390/molecules18067253 PMID: 23783459
4. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. (1998) Cyclooxygenase in biology and disease. Faseb J. 12(12):1063–1073. PMID: 9737710
5. Wang D, Mann JR, DuBois RN (2005) The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128(5):1445–1461. PMID: 15887126
6. Eberhart CE, Coffey RJ, Radyhka A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107(4):1183–1188. PMID: 7926468
7. Gupta RA, DuBois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1(1):11–21. PMID: 11900248
8. Marnett LJ, DuBois RN (2002) COX-2: A Target for Colon Cancer Prevention. Annu Rev Pharmacol Toxicol 42:55–80. PMID: 11807164
9. Ogino S, Kikkeri GJ, Noshok K, Irahara N, Kure S, Shiina K, et al. (2008) Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 14(24):8221–8227. doi: 10.1158/1078-0432.CCR-08-1841 PMID: 19088039
10. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K (2004) Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10(24):8465–8471. PMID: 15623626
11. Chan AT, Giovannucci EL, Meyerhardt JA, Schemhammer ES, Wu K, Fuchs CS (2008) Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134(1):21–28. PMID: 18005980
12. Tsujii M (2013) Cyclooxygenase, cancer stem cells and DNA methylation play important roles in colorectal carcinogenesis. Digestion 87(1):12–16. doi: 10.1159/000343898 PMID: 2334963
13. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP (2000) Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res 60(15):4044–4048. PMID: 10945606
14. Michikawa Y, Yasuda H, Watanabe Y, Oikawa R, Ohishi Y, Maehata T, et al. (2013) COX-2 Gene Promoter Methylation in Patients Infected with Helicobacter Pylori. Clin Med Insights Gastroenterol 6:13–19. doi: 10.4137/C Gast.00156 PMID: 24833939

15. Hamon MA, Cossart P (2008) Histone modifications and chromatin remodeling during bacterial infections. Cell Host Microbe 4(2):100–109. doi: 10.1016/j.chom.2008.07.009 PMID: 18692770

16. Minárovits J (2009) Microbe-induced epigenetic alterations in host cells: the coming era of patho-epigenetics of microbial infections. A review. Acta Microbiol Immunol Hung 56(1):1–19. doi: 10.1556/AMicr.56.2009.1.1 PMID: 19388554

17. Angrisano T, Pero R, Peluso S, Keller S, Sacchetti S, Bruni CB, et al. (2010) LPS-induced IL-8 activation of LPS-dependent COX-2 expression in human intestinal epithelial cells is accompanied by specific histone H3 acetylation and methylation changes. BMC Microbiol 10:172 doi: 10.1186/1471-2180-10-172 PMID: 20546607

18. Pero R, Peluso S, Angrisano T, Tuccillo C, Sacchetti S, Keller S, et al. (2011) Chromatin and DNA methylation dynamics of Helicobacter pylori-induced COX-2 activation. Int J Med Microbiol 301 (2):140–149. doi: 10.1016/j.jmim.2010.06.009 PMID: 20934379

19. Angrisano T, Lemo F, Peluso S, Keller S, Chiariotti L, Pero R (2012). Helicobacter pylori regulates iNOS promoter by histone modifications in human gastric epithelial cells. Med Microbiol Immunol 201 (3):249–257 doi:10.1007/s00430-011-0227-9 PMID: 22215089

20. Chiariotti L, Angrisano T, Keller S, Florio E, Affinito O, Pallante P et al. (2013) Epigenetic modifications induced by Helicobacter pylori infection through a direct microbe-gastric epithelial cells cross-talk. Med Microbiol Immunol 202(5):327–337. doi:10.1007/s00430-013-0301-6 PMID: 23715627

21. Suzuki M, Hisamatsu T, Podolsky DK (2003) Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex. Infect Immun 71(6):3503–3511. PMID: 12761135

22. Tagliaferri D, De Angelis MT, Russo NA, Marotta M, Ceccarelli M, Del Vecchio L, et al. (2016) Retinoic Acid Specifically Enhances Embryonic Stem Cell Metastate Marked by Zscan4. PLoS One 11(2): e0147683. doi: 10.1371/journal.pone.0147683 PMID: 26840068

23. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DeltaDelta C(T)) Method Methods 25(4):402–408. PMID: 11844609

24. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, et al. (2005) Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 44(44):15785–15790.

25. Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10(5):295–304. doi: 10.1038/nrg2540 PMID: 19308066

26. de Santa F, Narang V, Tap ZH, Tusi BK, Burgold T, Austenaa L, et al. (2009) Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J 28(21):3341–3352. doi: 10.1038/embj.2009.271 PMID: 19779457

27. Mehta S, Jeffrey KL (2015) Beyond receptors and signaling: epigenetic factors in the regulation of innate immunity. Immunol Cell Biol 93(3):233–244. doi: 10.1038/icb.2014.101 PMID: 25559622

28. Park GY, Joo M, Pedchenko T, Blackwell TS, Christman JW (2004) Regulation of macrophage cyclooxygenase-2 gene expression by modifications of histone H3. Am J Physiol Lung Cell Mol Physiol 286 (5):L956–962. PMID: 14672923

29. Weinmann AS, Plevy SE, Smale ST (1999) Rapid and selective remodeling of a positioned nucleosome during the induction of IL-12 p40 transcription. Immunity 11(6):665–675. PMID: 10626889

30. Boros J, Arnoult N, Stroobant V, Collet JF, Decottignies A (2014) Polycistronic repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1α at chromatin. Mol Cell Biol 34(19):3662–3674. doi: 10.1128/MCB.00205-14 PMID: 25047840

31. Kangaspeska S, Stride B, Mélivier R, Polycarpou-Schwarz M, Iberson D, Carmouche RP, et al. (2008). Transient cyclical methylation of promoter DNA. Nature 452(7183):112–115. doi: 10.1038/ nature06640 PMID: 18322535

32. Mélivier R, Gallais R, Tiffoche C, Le Péron C, Jurkowska RZ, Carmouche RP, et al. (2008) Cyclical DNA methylation of a transcriptionally active promoter. Nature 452(7183):45–50. doi: 10.1038/ nature06544 PMID: 18322525

33. Dhiman VK, Attwood K, Campbell MJ, Smiraglia DJ (2015) Hormone stimulation of androgen receptor mediates dynamic changes in DNA methylation patterns at regulatory elements. Oncotarget 6 (40):42575–42589. doi: 10.18632/oncotarget.6471 PMID: 26646795